JAGX · Jaguar Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.27M | - | $3.08M | $2.72M | $2.35M | - | $2.81M | - | - | - |
| Cost of Revenue | $1.16M | - | $532.0K | $527.0K | $515.0K | - | $541.0K | $427.0K | $430.0K | - |
| Gross Profit | $19.11M | - | $2.55M | $2.19M | $1.84M | - | $2.27M | - | - | - |
| R&D | $3.93M | - | $3.66M | $3.27M | $3.73M | - | $4.04M | $3.65M | $4.31M | - |
| SG&A | $4.11M | - | $4.13M | $4.73M | $4.90M | - | $3.78M | $4.31M | $4.38M | - |
| Total Operating Expenses | $10.09M | - | $10.32M | $10.99M | $11.63M | - | $10.37M | $9.92M | $10.57M | - |
| D&A | $473.0K | - | - | - | $479.0K | - | - | - | $501.0K | - |
| Operating Income | $10.18M | - | ($7.24M) | ($8.01M) | ($9.42M) | - | ($7.26M) | ($7.20M) | ($8.21M) | - |
| Interest Expense | $699.0K | - | $6.0K | ($15.0K) | ($56.0K) | - | ($162.0K) | ($108.0K) | $611.0K | - |
| Income Tax | $0 | - | - | - | - | - | $0 | $0 | $0 | - |
| Net Income | ($7.01M) | - | ($9.50M) | ($10.41M) | ($10.46M) | - | ($9.85M) | ($9.49M) | ($9.23M) | - |
| EPS - Basic | ($13.60) | - | ($219.80) | ($359.10) | ($584.50) | - | ($918.75) | ($3535.00) | ($3150.00) | - |
| EPS - Diluted | ($13.60) | - | ($219.80) | ($359.10) | ($584.50) | - | ($918.75) | ($3535.00) | ($3150.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.28M | $968.0K | $3.53M | $2.21M | $5.69M | $8.00M | $13.27M | $16.05M | $11.67M | $6.47M |
| Accounts Receivable | $68.0K | $1.52M | $1.44M | $1.17M | $1.22M | $1.53M | $1.25M | $1.30M | $1.51M | $1.97M |
| Inventory | $7.82M | $8.60M | $10.63M | $10.72M | $10.55M | $10.35M | $9.67M | $9.56M | $9.02M | $9.19M |
| Accounts Payable | $4.96M | $8.69M | $8.44M | $6.62M | $7.03M | $5.29M | $4.55M | $4.09M | $3.32M | $4.97M |
| Current Assets | $20.21M | $20.34M | $29.40M | $27.90M | $30.44M | $32.20M | $36.64M | $40.11M | $33.71M | $27.96M |
| Total Assets | $37.43M | $38.32M | $49.47M | $48.27M | $51.46M | $53.42M | $58.47M | $61.46M | $55.39M | $50.76M |
| Current Liabilities | $40.69M | $40.65M | $36.12M | $29.22M | $28.21M | $19.70M | $19.87M | $19.13M | $17.81M | $13.99M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $53.19M | $57.01M | $45.11M | $41.39M | $48.15M | $44.45M | $42.88M | $42.40M | $41.09M | $45.87M |
| Stockholders' Equity | ($15.75M) | ($18.69M) | $4.36M | $6.88M | $830.0K | $6.49M | $13.10M | $16.58M | $11.82M | $4.90M |
| Retained Earnings | ($391.07M) | ($399.92M) | ($376.86M) | ($367.35M) | ($356.95M) | ($346.48M) | ($336.56M) | ($326.71M) | ($317.21M) | ($308.25M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $8.83M | - | - | - | ($7.32M) | - | - | - | ($7.05M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | ($6.62M) | - | - | - | $4.97M | - | - | - | $12.27M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 94.3% | - | 82.7% | 80.6% | 78.1% | - | 80.8% | - | - | - |
| Operating margin | 50.2% | - | -234.8% | -294.3% | -400.7% | - | -258.2% | - | - | - |
| EBITDA margin | 52.6% | - | - | - | -380.3% | - | - | - | - | - |
| Net margin | -34.6% | - | -308.2% | -382.5% | -445.1% | - | -350.3% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 19.4% | - | 118.7% | 120.0% | 158.7% | - | 143.7% | - | - | - |
| SG&A / Revenue | 20.3% | - | 134.1% | 173.7% | 208.3% | - | 134.2% | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -18.7% | - | -19.2% | -21.6% | -20.3% | - | -16.9% | -15.4% | -16.7% | - |
| Return on equity | 44.5% | - | -218.0% | -151.3% | -1260.7% | - | -75.2% | -57.3% | -78.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.50 | 0.50 | 0.81 | 0.95 | 1.08 | 1.63 | 1.84 | 2.10 | 1.89 | 2.00 |
| Quick ratio | 0.30 | 0.29 | 0.52 | 0.59 | 0.70 | 1.11 | 1.36 | 1.60 | 1.39 | 1.34 |
| Cash ratio | 0.18 | 0.02 | 0.10 | 0.08 | 0.20 | 0.41 | 0.67 | 0.84 | 0.66 | 0.46 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 14.6x | - | -1206.3x | 533.8x | 168.2x | - | 44.8x | 66.6x | -13.4x | - |
| Equity multiplier | -2.38 | -2.05 | 11.35 | 7.02 | 62.00 | 8.23 | 4.46 | 3.71 | 4.69 | 10.37 |
| Liabilities / Assets | 1.42 | 1.49 | 0.91 | 0.86 | 0.94 | 0.83 | 0.73 | 0.69 | 0.74 | 0.90 |
| Efficiency | ||||||||||
| Asset turnover | 0.54 | - | 0.06 | 0.06 | 0.05 | - | 0.05 | - | - | - |
| Inventory turnover | 0.15 | - | 0.05 | 0.05 | 0.05 | - | 0.06 | 0.04 | 0.05 | - |
| Days sales outstanding | 1d | - | 170d | 157d | 190d | - | 162d | - | - | - |
| Days inventory outstanding | 2465d | - | 7292d | 7424d | 7481d | - | 6527d | 8168d | 7657d | - |
| Days payable outstanding | 1562d | - | 5793d | 4583d | 4981d | - | 3071d | 3499d | 2818d | - |
| Cash conversion cycle | 903d | - | 1669d | 2998d | 2690d | - | 3618d | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 28.3x | 13.0x | 125.8x | - | 845.1x | 443.9x | 63507.3x | - |
| P / S | 0.3x | - | 40.0x | 32.9x | 44.4x | - | 3934.8x | - | - | - |
| EV / EBITDA | -0.1x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 762.3% | - | 9.6% | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | 2.1% | -3.0% | 22.0% | - | 23.7% | - | - | - |
| Gross profit growth (YoY) | 941.1% | - | 12.3% | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 0.3% | -11.3% | -14.7% | - | 17.4% | 11.2% | 16.6% | - |
| Net income growth (YoY) | 33.0% | - | 3.6% | -9.6% | -13.4% | - | -26.7% | 21.9% | 48.7% | - |
| EPS growth (YoY) | 97.7% | - | 76.1% | 89.8% | 81.4% | - | -241676.3% | -841566.7% | -131699.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -66.7% | -58.5% | -93.0% | 32.6% | 825.0% | 184.5% | 54.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$11.51M totalHuman Health Segment$11.16M · 96.9%
Animal Health Segment$353.0K · 3.1%
Product / service
$22.69M totalProduct$11.34M · 50.0%
Mytesi$11.00M · 48.5%
License$172.0K · 0.8%
Canalevia$148.0K · 0.7%
Neonorm$35.0K · 0.2%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Jaguar Health against the 5 most active filers in the same SIC group.